Brain Magnetic Resonance Imaging at 3.0 Tesla in neurodegenerative parkinsonism – a pilot study

Recruiting

• Conditions: G20; G23.1; G90.3; Parkinson disease; Progressive supranuclear ophthalmoplegia [Steele-Richardson-Olszewski]

• Registration Number: DRKS00003299
• Lead Sponsor: Medizinische Universität Innsbruck,Department für Neurologie

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2011-10-14
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

patients:
1. clinical diagnosis of PD, MSA or PSP obtained by a neurologist according to published clinical diagnostic criteria;
2. the patient has the ability to communicate well with the investigator and comply with the requirements of the study;
3. written informed consent is obtained;

healthy controls:
1. the subject has the ability to communicate well with the investigator and comply with the requirements of the study;
2. written informed consent is obtained;

Exclusion Criteria

patients:
1. History of other neurological or psychiatric disorders or conditions;
2. the subject has a history of alcohol, narcotic, or any other drug abuse as defined by the Diagnostic and Statistical Manual of the American Psychiatric Association, 4th Edition (DSM-IV);
3. the subject is pregnant;
4. the subject is unsuitable for an MRI study (e.g. Pacemakers);

healthy controls:
1. History of neurological or psychiatric disorders or conditions;
2. the subject has a history of alcohol, narcotic, or any other drug abuse as defined by the Diagnostic and Statistical Manual of the American Psychiatric Association, 4th Edition (DSM-IV);
3. the subject is pregnant;
4. the subject is unsuitable for an MRI study

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To assess the diagnostic value of structural MR findings using routine MRI sequences (T2, T1) at 3.0T versus 1.5T to detect atrophy or signal changes in basal ganglia and infratentorial structures for differential diagnosis of neurodegenerative parkinsonism.

Secondary Outcome Measures

Name	Time	Method
1. To identify structural changes (atrophy, signal changes) in regional brain structures that distinguish APD from PD and healthy controls and that distinguish between the different APDs; 2. To identify DWI/DTI changes in regional brain structures that distinguish PD from healthy controls; 3. To identify DWI/DTI changes in regional brain structures that distinguish APD from PD and healthy controls and that distinguish between the different APDs; 4. To identify grey or white matter changes in regional brain structures using VBM that distinguish APD from patients with PD and healthy controls as well as between the different APDs.